Using immunoglobulins in muscular disease treatment

Expert Opinion on Biological Therapy

Volumn 8, Issue 8, 2008, Pages 1143-1150

  Pul, Refik ^a   Stangel, Martin ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Dermatomyositis; Inclusion myositis; Intravenous immunoglobulin; Lambert Eaton myasthenic syndrome; Muscular diseases; Myasthenia gravis; Polymyositis; Stiff person syndrome

Indexed keywords

3,4 DIAMINOPYRIDINE; AZATHIOPRINE; CHLORAMBUCIL; CHLORPHENIRAMINE; CLONAZEPAM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIAZEPAM; GABAPENTIN; HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; METHOTREXATE; PLACEBO; PREDNISONE; PYRIDOSTIGMINE; STEROID; TIAGABINE;

ADD ON THERAPY; ADJUVANT THERAPY; CLINICAL TRIAL; CONTINUOUS INFUSION; DERMATOMYOSITIS; DRUG DOSE REDUCTION; DRUG EFFICACY; EATON LAMBERT SYNDROME; HUMAN; IDIOPATHIC DISEASE; INCLUSION BODY MYOSITIS; MEDLINE; MUSCLE DISEASE; MYASTHENIA GRAVIS; PLASMAPHERESIS; POLYMYOSITIS; REVIEW; STIFF MAN SYNDROME; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LAMBERT-EATON MYASTHENIC SYNDROME; MYASTHENIA GRAVIS; MYOSITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STIFF-PERSON SYNDROME;

EID: 47949100360     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.8.1143     Document Type: Review

References (61)

1. Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228-31
2. Stangel M, Gold R. Use of i.v. immunoglobulins in neurology. Evidence-based consensus. Nervenarzt 2004;75:801-15
3. Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev 2007;21:S57-107
4. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82
5. Callen JP, Wortmann RL. Dermatomyositis. Clin Dermatol 2006;24:363-73
6. Mastaglia FL, Garlepp MJ, Phillips BA, Zilko PJ. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 2003;27:407-25
7. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000
8. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729-35
9. Marie I, Hachulla E, Levesque H, et al. Intravenous immunoglobulins as treatment of life threatening esophageal involvement in polymyositis and dermatomyositis. J Rheumatol 1999;26:2706-9
10. Al Mayouf SM, Laxer RM, Schneider R, et al. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 2000;27:2498-503
11. Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis - four year review of nine cases. Arch Dis Child 1995;72:25-8
12. van der Meulen MR, Bronner IM, Hoogendijk JE, et al. Polymyositis: an overdiagnosed entity. Neurology 2003;61:316-21
13. Hengstman GJ, van Engelen BG. Polymyositis, invasion of non-necrotic muscle fibres, and the art of repetition. BMJ 2004;329:1464-7
14. Gelfand EW. The use of intravenous immune globulin in collagen vascular disorders: a potentially new modality of therapy. J Allergy Clin Immunol 1989;84:613-5
15. Cherin P, Herson S, Wechsler B, et al. Effectiveness of intravenous immunoglobulins in polymyositis and dermatomyositis. An open trial in 15 patients. Presse Med 1991;20:244-9
16. Saito M, Saito Y, Endo K, Tanaka M. A case of steroid-resistant polymyositis who made a good response to high dose intravenous immunoglobulins (IVIG). Rinsho Shinkeigaku 2000;40:181-3
17. Moriguchi M, Suzuki T, Tateishi M, et al. Intravenous immunoglobulin therapy for refractory myositis. Intern Med 1996;35:663-7
18. Jann S, Beretta S, Moggio M, et al. High-dose intravenous human immunoglobulin in polymyositis resistant to treatment. J Neurol Neurosurg Psychiatry 1992;55:60-2
19. Danieli MG, Malcangi G, Palmieri C, et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 2002;61:37-41
20. Cherin P, Piette JC, Wechsler B, et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol 1994;21:1092-7
21. Cherin P, Pelletier S, Teixeira A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002;46:467-74
22. Wiles CM, Brown P, Chapel H, et al. Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry 2002;72:440-8
23. Dalakas MC. Sporadic inclusion body myositis - diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2006;2:437-47
24. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007;6:620-31
25. Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993;43:876-9
26. Amato AA, Barohn RJ, Jackson CE, et al. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1994;44:1516-8
27. Dalakas MC, Sonies B, Dambrosia J, et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997;48:712-6
28. Walter MC, Lochmüller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000;247:22-8
29. Dalakas MC, Koffman B, Fujii M, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001;56:323-7
30. Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 2002;58:326
31. Sparks S, Rakocevic G, Joe G, et al. Intravenous immune globulin in hereditary inclusion body myopathy: a pilot study. BMC Neurol 2007;7(3): published online 29 January 2007, doi:10.1186/1471-2377-7-3
32. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest 2006;116:2843-54
33. Juel VC. Myasthenia gravis: management of myasthenic crisis and perioperative care. Semin Neurol 2004;24:75-81
34. Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997;41:789-96
35. Gajdos P, Tranchant C, Clair B, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol 2005;62:1689-93
36. Qureshi Al, Choudhry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999;52:629-32
37. Ronager J, Ravnborg M, Hermansen I, Vorstrup S. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs 2001;25:967-73
38. Wolfe GI, Barohn RJ, Foster BM, et al. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 2002;26:549-52
39. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007;68:837-41
40. Achiron A, Barak Y, Miron S, Sarova-Pinhas I. Immunoglobulin treatment in refractory Myasthenia gravis. Muscle Nerve 2000;23:551-5
41. Maddison P. Neuromyotonia. Clin Neurophysiol 2006;117:2118-27
42. Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996;47:678-83
43. Muchnik S, Losavio AS, Vidal A, et al. Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin. Muscle Nerve 1997;20:674-8
44. Bird SJ. Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy. Neurology 1992;42:1422-3
45. Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2005;CD003279. Published online 20 April 2005, doi: 10.1002/14651858.CD003279.pub2
46. Murinson BB. Stiff-person syndrome. Neurologist 2004;10:131-7
47. Dalakas MC, Fujii M, Li M, McElroy B. The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology 2000;55:1531-5
48. Meinck HM, Thompson PD. Stiff man syndrome and related conditions. Mov Disord 2002;17:853-66
49. Dalakas MC, Fujii M, Li M, et al. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 2001;345:1870-6
50. Silbert PL, Matsumoto JY, McManis PG, et al. Intrathecal baclofen therapy in stiff-man syndrome: a double-blind, placebo-controlled trial. Neurology 1995;45:1893-7
51. Stayer C, Tronnier V, Dressnandt J, et al. Intrathecal baclofen therapy for stiff-man syndrome and progressive encephalomyelopathy with rigidity and myoclonus. Neurology 1997;49:1591-7
52. Gold R, Stangel M, Dalakas MC. Drug Insight: the use of intravenous immunoglobulin in neurology- therapeutic considerations and practical issues. Nat Clin Pract Neurol 2007;3:36-44
53. Stangel M, Pul R. Basic principles of intravenous immunoglobulin (IVIg) treatment. J Neurol 2006;253:v18-24
54. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-55
55. Nimmerjahn F, Ravetch JV The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 2007;204:11-5
56. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 2005;310:1510-2
57. Clynes R. IVIG therapy: interfering with interferon-γ. Immunity 2007;26:4-6
58. Raju R, Dalakas MC. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 2005;128:1887-96
59. Barbasso Helmers S, Dastmalchi M, Alexanderson H, et al. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. Ann Rheum Dis 2007;66:1276-83
60. Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: their neutralization by intravenous immunoglobulins. Muscle Nerve 2005;31:487-94
61. Bayry J, Kazatchkine MD, Kaveri SV. Shortage of human intravenous immunoglobulin-reasons and possible solutions. Nat Clin Pract Neurol 2007;3:120-1 Hannover Medical School, Department of Neurology, Carl-Neuberg-Street 1, 30625 Hannover, Germany